Zanubrutinib

Generic Name
Zanubrutinib
Brand Names
Brukinsa
Drug Type
Small Molecule
Chemical Formula
C27H29N5O3
CAS Number
1691249-45-2
Unique Ingredient Identifier
AG9MHG098Z
Background

Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...

Indication

Zanubrutinib is indicated for the treatment of:

Associated Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
Associated Therapies
-

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
Conditions
Interventions
First Posted Date
2024-06-04
Last Posted Date
2024-06-04
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Target Recruit Count
125
Registration Number
NCT06441214
Locations
🇮🇹

Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia, Firenze, Italy

🇮🇹

A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia, Alessandria, Italy

🇮🇹

A.O.U. Ospedali Riuniti - Clinica di Ematologia, Ancona, Italy

and more 25 locations

A Study of GFH009 in Combination with Zanubrutinib in Subjects with Relapsed or Refractory DLBCL

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-04-19
Last Posted Date
2024-12-13
Lead Sponsor
Genfleet Therapeutics (Shanghai) Inc.
Target Recruit Count
51
Registration Number
NCT06375733
Locations
🇨🇳

Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Nanning, China

🇨🇳

Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital, Zhengzhou, China

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

First Posted Date
2024-04-16
Last Posted Date
2024-04-16
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
66
Registration Number
NCT06367374

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

First Posted Date
2024-04-05
Last Posted Date
2024-10-01
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
43
Registration Number
NCT06350318
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2024-04-02
Last Posted Date
2024-04-02
Lead Sponsor
Fudan University
Target Recruit Count
52
Registration Number
NCT06341556
Locations
🇨🇳

Shanghai Cancer Center, Shanghai, Shanghai, China

🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

First Posted Date
2023-12-13
Last Posted Date
2024-03-12
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
76
Registration Number
NCT06167785

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

First Posted Date
2023-11-18
Last Posted Date
2023-11-29
Lead Sponsor
Ruijin Hospital
Target Recruit Count
23
Registration Number
NCT06136351
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2023-10-10
Last Posted Date
2024-12-13
Lead Sponsor
BeiGene
Target Recruit Count
640
Registration Number
NCT06073821
Locations
🇺🇸

John Muir Medical Center, Concord, California, United States

🇺🇸

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States

🇺🇸

UCLA Department of Medicine Hematologyoncology, Los Angeles, California, United States

and more 228 locations

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-09-08
Last Posted Date
2024-05-17
Lead Sponsor
Alvaro Alencar, MD
Target Recruit Count
27
Registration Number
NCT06029309
Locations
🇺🇸

University of Miami, Miami, Florida, United States

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

First Posted Date
2023-09-01
Last Posted Date
2023-11-29
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
33
Registration Number
NCT06021977
Locations
🇨🇳

Regenerative Medicine Center, Tianjin, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath